StockWatch
·

NATCO PHARMA LTD. Q2 FY27 Results

NATCOPHARMQ2 FY27 Results
Filing
Result:Weak· Market: Flat#Base effect#One-off hit#Margin squeeze
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue967.3031.6%29.0%
Total Income1.0K28.3%30.3%
Expenditure776.2027.5%8.6%
PBT243.2031.0%60.4%
Net Profit202.601.9%60.9%
OPM26.66%1.29pp15.83pp
NPM19.87%6.12pp15.53pp
EPS11.311.9%60.9%
View full financials

Core revenue (-29% YoY) and PAT (-60.9% YoY) fell sharply as the Lenalidomide exclusivity spike normalized, with EBITDA margin compressing to 30.4% from 46.4%, though the QoQ stabilization keeps it off the floor of the weak band.

Q2 FY-2027 RESULTS · NATCOPHARM

Natco Q2 FY27: PAT down 61% YoY to ₹203 Cr (consolidated) as Lenalidomide fades

PAT -60.88% YoY · revenue -29.03% · margins compressing

13 Nov 2026 · 3 min read
Revenue

₹967.3 Cr

-29.03% YoY

PAT (consolidated)

₹202.6 Cr

-60.88% YoY

Net margin

19.87%

-15.5pp YoY

EPS

₹11.31

Natco Pharma's consolidated profit for Q2 FY27 came in at ₹202.6 Cr, down 60.9% year-on-year from ₹517.9 Cr and essentially flat quarter-on-quarter (-1.9% versus ₹206.5 Cr). Consolidated revenue from operations of ₹967.3 Cr fell 29.0% YoY but rose 31.6% QoQ. The YoY comparison is the one that matters here: Q2 FY26 was inflated by an exclusivity-driven Lenalidomide (generic Revlimid) spike in the US that has since normalised, and management's own press release attributes the YoY decline "largely" to lower Lenalidomide revenue, partly offset by growth in the base business and subsidiaries. International Formulations revenue (including subsidiaries) nearly halved YoY to ₹668.4 Cr from ₹1,140.2 Cr, even as it rose from ₹477.1 Cr in Q1 FY27 — the QoQ pickup looks like a stabilising base business, not a reversal of the structural Lenalidomide decline.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹967.3 Cr+31.6%-29%
Expenses₹776.2 Cr+27.5%-8.6%
PAT₹202.6 Cr-1.89%-60.88%
Net margin19.87%-6.1pp-15.5pp
EPS₹11.31-1.9%-60.9%

Margins compressed on both comparisons: EBITDA margin before share of associate fell to 30.4% from 46.4% a year ago (roughly flat versus 30.9% in Q1), and net margin on total income slid to about 19.9% from 35.4% YoY and 26.0% QoQ. The sequential margin stability, alongside a 31.6% QoQ revenue recovery, suggests the base pharmaceuticals and agrochemical businesses are no longer deteriorating quarter-on-quarter even as the YoY base effect from Lenalidomide persists. ₹29.2 Cr of the consolidated PAT came from NATCO's 49%-owned associate Adcock Ingram Holdings (South Africa, revenue ₹1,343.8 Cr, PAT ₹80.5 Cr for the quarter) — down from an unusually large ₹84.3 Cr associate contribution in Q1 that reflected provisional purchase-price-accounting adjustments after the stake increase; this makes the QoQ PAT comparison a little noisier than the headline flat print suggests. Standalone PAT of ₹143.2 Cr was down a sharper 71.4% YoY (versus consolidated's 60.9%), a double-digit-point divergence from the consolidated story driven mainly by the associate profit share and subsidiary earnings that sit outside the standalone entity — both numbers will circulate, and the gap is explained by consolidation scope, not a data error.

₹
761.19813.92866.65919.38972.11782.4508-1009-0109-2410-1911-1111-13Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹782.45, down 0% over the past month of trading.

₹ Cr
0193.35386.7580.05480.3Q1 FY26rev ₹1,329 Cr517.9Q2 FY26rev ₹1,363 Cr151.3Q3 FY26rev ₹647 Cr269Q4 FY26rev ₹739 Cr206.5Q1 FY27rev ₹735 Cr202.6Q2 FY27rev ₹967 Cr
Quarterly consolidated PAT, ₹ Crore
What management guided (1 FY-2027 call)
FY27: Revenue 3,400-3,500 Cr (but Q1 at 735 Cr annualizes to ~2,940 Cr); PAT 700-750 Cr (maintained despite Q1 weakness). Capex ~250-300 Cr/year ongoing.

— This quarter: missed

Against management's own FY27 guidance (revenue ₹3,400-3,500 Cr, PAT ₹700-750 Cr, given on the Q1 call under a cautious, high-risk tone), H1 FY27 revenue from operations of ₹1,702.5 Cr annualises to roughly ₹3,405 Cr — inside the guided band, a genuine improvement on the ~₹2,940 Cr pace flagged after Q1's weak start. PAT is murkier: H1 profit before the associate's share was ₹295.6 Cr, annualising to ~₹591 Cr, below the ₹700-750 Cr guided range; only once the outsized Q1 associate contribution is folded in does the H1 total of ₹409.1 Cr annualise above guidance (~₹818 Cr), a result that leans on a provisional, acquisition-related accounting item rather than recurring operations. On balance this reads as tracking below the PAT guidance on a core basis. We found no quarter-specific Street consensus for this print to grade against (vsStreet unknown); a web search surfaced only a full-year FY27 analyst estimate materially below even management's own guidance, underscoring that the market has been pricing a tougher outcome than the company's stated band. The quarter's corporate actions — a completed ₹1,279 Cr rights issue (1.7 Cr shares at ₹750 each) and a second interim dividend of ₹1.25/share declared alongside results — both land after the Lenalidomide-driven profit base has already reset lower, and tie to funding the expanded Adcock Ingram stake and the company's ongoing ₹250-300 Cr/year capex plan.

  • W1

    Management has said Q2 FY27 was the last meaningful quarter for Lenalidomide, with Q3/Q4 contributions expected to be negligible — watch whether the base business can hold the ~₹967 Cr quarterly revenue run-rate without it.

  • W2

    FY27 guidance of ₹700-750 Cr PAT implies H2 must deliver well above the ~₹591 Cr annualised core (ex-associate) run-rate seen in H1 — watch Q3 PAT for signs of a step-up.

  • W3

    Adcock Ingram associate stake now at 49% with provisional PPA still being finalised — watch for the PPA to be trued up and the associate's profit contribution to normalise from Q1's elevated ₹84.3 Cr.

Figures converted from ₹ in millions (÷10). Consolidated PAT (₹202.6 Cr) = PBT−tax (₹173.4 Cr) + ₹29.2 Cr share of profit of associate Adcock Ingram (stake raised to 49% this quarter, provisional PPA); standalone arithmetic ties exactly. Prior-quarter/year-ago revenue, PAT and EPS all cross-checked to the exact decimal against the company's own comparative columns.

Informational and educational content only. Not investment advice.